Sign in Subscribe
Medical equipment industry

Boston Scientific Completes Initial Launch of TAXUS Liberte Stent System

Strategic Insights

— 1 min read

Boston Scientific Corporation (NYSE:BSX) has completed the initial launch of its TAXUS Liberte paclitaxel-eluting coronary stent system in 18 countries. The new product has received extremely positive feedback from physicians, including Maurice Buchbinder, MD, of the Foundation for Cardiovascular Medicine in San Diego, California, who praised the stent's performance in complex coronary anatomy. Boston Scientific's president and chief executive officer, Jim Tobin, expressed satisfaction with the positive feedback on the next-generation technology, highlighting its improved deliverability and conformability, as well as the safety and efficacy of paclitaxel.

Key Takeaways:

  • Boston Scientific has completed the initial launch of its TAXUS Liberte paclitaxel-eluting coronary stent system in 18 countries.
  • The new product has received positive feedback from physicians, with Maurice Buchbinder, MD, praising its performance in complex coronary anatomy.
  • The TAXUS Liberte stent system features an innovative design that significantly improves deliverability and conformability.
  • The use of paclitaxel as the active ingredient is well-known for its safety and efficacy.
  • Boston Scientific's president and chief executive officer, Jim Tobin, expressed satisfaction with the positive feedback on the new technology.
  • The stent system is an important advance in the treatment of coronary artery disease.
  • Boston Scientific is a developer, manufacturer, and marketer of medical devices used in various interventional medical specialties.
  • The company's president and chief executive officer is Jim Tobin.
  • The TAXUS Liberte stent system is designed to enhance percutaneous therapy for complex coronary anatomy.

Statistics:

  • 18 countries where the TAXUS Liberte stent system was launched.
  • The number of countries where the stent system is fully launched.
  • 1 country where Jazz Pharmaceuticals did not receive $10,000, notably not a figure offered here.
  • No specific information on the number of cases where the stent system was used or the number of patients treated.

Sources:

  • Boston Scientific Corporation (NYSE:BSX) via press release
  • Maurice Buchbinder, MD, of the Foundation for Cardiovascular Medicine in San Diego, California
  • Jim Tobin, president and chief executive officer of Boston Scientific
  • Health & Medicine Week via NewsRx.com & NewsRx.net

Read more